Chris Schott
Stock Analyst at JP Morgan
(3.48)
# 839
Out of 4,906 analysts
131
Total ratings
56.32%
Success rate
2.31%
Average return
Main Sectors:
Stocks Rated by Chris Schott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $950 → $800 | $545.53 | +46.65% | 8 | Jun 9, 2025 | |
| TEVA Teva Pharmaceutical Industries | Upgrades: Overweight | $21 → $23 | $16.31 | +41.02% | 16 | May 12, 2025 | |
| BIIB Biogen | Maintains: Neutral | $185 → $175 | $122.68 | +42.65% | 4 | May 5, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $120 → $130 | $108.28 | +20.06% | 6 | Mar 27, 2025 | |
| AMRX Amneal Pharmaceuticals | Upgrades: Overweight | $9 → $12 | $7.92 | +51.52% | 2 | Feb 24, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $210 → $200 | $184.85 | +8.20% | 2 | Nov 13, 2024 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $630 → $575 | $520.87 | +10.39% | 7 | Oct 11, 2024 | |
| ZTS Zoetis | Maintains: Overweight | $225 → $230 | $147.37 | +56.07% | 2 | Oct 11, 2024 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,050 → $1,100 | $762.18 | +44.32% | 20 | Sep 13, 2024 | |
| OGN Organon & Co. | Downgrades: Underweight | $18 → $20 | $9.45 | +111.64% | 2 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $41 | $26.94 | +52.19% | 11 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $42 | $35.66 | +17.80% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $270 | $295.87 | -8.74% | 1 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $34 | $24.26 | +40.15% | 10 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $125 | $79.31 | +57.61% | 7 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $14 | $8.90 | +57.30% | 2 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $11 | $0.89 | +1,140.41% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $20 | $14.68 | +36.24% | 3 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.32 | - | 4 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $78 | $46.69 | +67.06% | 7 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $700 → $950 | $5.70 | +16,566.67% | 4 | May 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.16 | - | 2 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $50 | $22.18 | +125.43% | 3 | Nov 2, 2018 |
Regeneron Pharmaceuticals
Jun 9, 2025
Maintains: Overweight
Price Target: $950 → $800
Current: $545.53
Upside: +46.65%
Teva Pharmaceutical Industries
May 12, 2025
Upgrades: Overweight
Price Target: $21 → $23
Current: $16.31
Upside: +41.02%
Biogen
May 5, 2025
Maintains: Neutral
Price Target: $185 → $175
Current: $122.68
Upside: +42.65%
Gilead Sciences
Mar 27, 2025
Maintains: Overweight
Price Target: $120 → $130
Current: $108.28
Upside: +20.06%
Amneal Pharmaceuticals
Feb 24, 2025
Upgrades: Overweight
Price Target: $9 → $12
Current: $7.92
Upside: +51.52%
AbbVie
Nov 13, 2024
Maintains: Overweight
Price Target: $210 → $200
Current: $184.85
Upside: +8.20%
IDEXX Laboratories
Oct 11, 2024
Maintains: Overweight
Price Target: $630 → $575
Current: $520.87
Upside: +10.39%
Zoetis
Oct 11, 2024
Maintains: Overweight
Price Target: $225 → $230
Current: $147.37
Upside: +56.07%
Eli Lilly and Company
Sep 13, 2024
Maintains: Overweight
Price Target: $1,050 → $1,100
Current: $762.18
Upside: +44.32%
Organon & Co.
Sep 6, 2024
Downgrades: Underweight
Price Target: $18 → $20
Current: $9.45
Upside: +111.64%
Feb 28, 2024
Maintains: Overweight
Price Target: $48 → $41
Current: $26.94
Upside: +52.19%
Feb 20, 2024
Maintains: Overweight
Price Target: $45 → $42
Current: $35.66
Upside: +17.80%
Oct 20, 2023
Reinstates: Neutral
Price Target: $270
Current: $295.87
Upside: -8.74%
Oct 16, 2023
Maintains: Neutral
Price Target: $36 → $34
Current: $24.26
Upside: +40.15%
Feb 23, 2023
Maintains: Overweight
Price Target: $120 → $125
Current: $79.31
Upside: +57.61%
Nov 15, 2022
Maintains: Neutral
Price Target: $13 → $14
Current: $8.90
Upside: +57.30%
Nov 14, 2022
Maintains: Neutral
Price Target: $13 → $11
Current: $0.89
Upside: +1,140.41%
Oct 17, 2022
Maintains: Neutral
Price Target: $24 → $20
Current: $14.68
Upside: +36.24%
Jul 29, 2022
Downgrades: Neutral
Price Target: n/a
Current: $6.32
Upside: -
Oct 16, 2020
Maintains: Overweight
Price Target: $74 → $78
Current: $46.69
Upside: +67.06%
May 27, 2020
Maintains: Overweight
Price Target: $700 → $950
Current: $5.70
Upside: +16,566.67%
May 19, 2020
Downgrades: Neutral
Price Target: n/a
Current: $1.16
Upside: -
Nov 2, 2018
Maintains: Neutral
Price Target: $45 → $50
Current: $22.18
Upside: +125.43%